LONDON (dpa-AFX) - CureVac N.V. (CVAC) published the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK. The data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty. Neutralizing antibody levels measured following full vaccination of animals with either 12µg of CV2CoV or a 30µg standard dose of Comirnaty were shown to be highly comparable, as per the study.
During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected than animals vaccinated with CVnCoV in the study.
Copyright RTT News/dpa-AFX
© 2021 AFX News
